

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



丽珠医药
LIVZON

麗珠醫藥集團股份有限公司

LIVZON PHARMACEUTICAL GROUP INC.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1513)

PRELIMINARY RESULTS ANNOUNCEMENT FOR THE FIRST THREE QUARTERS OF 2018

This announcement is made pursuant to Rule 13.09 (2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") and the Inside Information Provisions (as defined by the provisions of Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571) of the Laws of Hong Kong by Livzon Pharmaceutical Group Inc. 麗珠醫藥集團股份有限公司 (the "Company", together with its subsidiaries, the "Group").*

The Company and all members of the board of directors guarantee that the information stated in this announcement is true, accurate and complete and does not contain any false representation, misleading statement or material omission.

Important: The financial data for the first three quarters of 2018 set out in this announcement represents figures of preliminary estimations only and has not been audited by an auditing firm. As a result, differences may be found between the data below and the definitive financial data disclosed in the 2018 Third Quarterly Report of the Company. Investors are advised to be cautious about investment risks involved.

I. PRELIMINARY RESULTS FOR THE PERIOD

1. Period for the preliminary estimated results: 1 January 2018 to 30 September 2018, 1 July 2018 to 30 September 2018
2. Preliminary estimated operating results: Decrease over the corresponding period last year

Item	Current reporting period		Corresponding period last year	
	1 January 2018 to 30 September 2018	1 July 2018 to 30 September 2018	1 January 2017 to 30 September 2017	1 July 2017 to 30 September 2017
Net profit attributable to the shareholders of the listed company	Profit: approximately RMB 877.2129 million- RMB 950.3704 million Decreased by approximately 77.62% - 79.34% as compared to the corresponding period last year	Profit: approximately RMB 243.8586 million- RMB 317.0161 million Decreased by approximately 91.53% - 93.48% as compared to the corresponding period last year	Profit: RMB 4,246.2419 million	Profit: RMB 3,742.2394 million
Net profit attributable to the shareholders of the listed company after deducting the extraordinary gain or loss	Profit: approximately RMB 795.0213 million- RMB 862.1901 million Increased by approximately 17.06% - 26.95% as compared to the corresponding period last year	Profit: approximately RMB 223.8961 million- RMB 291.0649 million Increased by approximately 0.00% - 30.00% as compared to the corresponding period last year	Profit: RMB 679.1635 million	Profit: RMB 223.8961 million
Basic earnings per share (RMB/share)	Profit: approximately RMB 1.22 – RMB 1.33 per share	Profit: approximately RMB 0.34 – RMB 0.44 per share	Profit: RMB 5.97 per share	Profit: RMB 5.25 per share

Note: In June 2018, as a result of the implementation of conversion of capital reserve by the Company, earnings per share for the third quarter of 2017 has been adjusted based on the latest information of share capital in accordance with the requirement of applicable accounting standards.

II. AUDIT STATUS OF THE PRELIMINARY ESTIMATED RESULTS

The preliminary estimated results have not been audited by certified public accountants.

III. EXPLANATION FOR THE CHANGES IN RESULTS

The results of the Company for the first three quarters of 2018 have decreased as compared to the corresponding period last year, which is mainly attributable to:

1. On 18 April 2017, the Company and its subsidiary, Livzon Group Livzon Pharmaceutical Factory* (麗珠集團麗珠製藥廠) entered into an Equity Transfer Agreement with Zhuhai Hengqin Weichuang Fortune Investment Co., Ltd.* (珠海橫琴維創財富投資有限公司) in relation to the transfer of 100% equity interest in its subsidiary of Zhuhai Weixing Shiye Co., Ltd. (珠海維星實業有限公司). The equity transfer has been completed on 17 July 2017 and resulted in an increase of RMB3,284 million in the net profit attributable to the shareholders of the Company.

2. Excluding the extraordinary gains or losses, it is expected that the net profit attributable to the shareholders of the Company after deducting the extraordinary gain or loss from 1 January 2018 to 30 September 2018 would increase by 17.06% to 26.95% as compared to the same period last year, which was primary attributable to the stable principal businesses and the increase in interest income due to further optimization of capital management.

IV. OTHER RELEVANT INFORMATION

1. Figures related to this preliminary results announcement are arrived based on the preliminary estimations of the Company, and have not been audited by an auditing firm;

2. Detailed financial information will be disclosed in the 2018 Third Quarterly Report of the Company. Potential investors are advised to pay attention to the risks associated with the investment.

By order of the Board
麗珠醫藥集團股份有限公司
Livzon Pharmaceutical Group Inc.*
Yang Liang
Company Secretary

Zhuhai, China
17 August 2018

As at the date of this announcement, the Executive Directors of the Company are Mr. Tao Desheng (Vice Chairman and President), Mr. Fu Daotian (Vice President) and Mr. Xu Guoxiang (Vice President); the Non-Executive Directors of the Company are Mr. Zhu Baoguo (Chairman) and Mr. Qiu Qingfeng; and the Independent Non-Executive Directors of the Company are Mr. Xu Yanjun, Mr. Guo Guoqing, Mr. Wang Xiaojun, Mr. Zheng Zhihua and Mr. Xie Yun.

** For identification purpose only*